PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Molecular Systems, Inc.

USPTO PatentsView assignee record - 395 granted patents across 67 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

Explore the portfolio See the ranking
395
Total patents granted
67
CPC technology areas
11.7
Avg claims per patent
-12%
5-year filing velocity

The verdict

Roche holds 395 US patents across 67 technology areas, rank #1,083 of 50,000 tracked assignees.

#1,083
of 50,000 US assignees by volume
Top 5%
by Innovation Score (57.8/100)
11.7
avg claims per patent
-12%
filing velocity, last 5 yrs

Portfolio overview

Roche Molecular Systems, Inc. has been granted 395 US utility patents between 2015 and 2025, placing Roche Molecular Systems, Inc. at rank #1,083 across all assignees tracked by PlainPatent. This portfolio spans 67 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.7 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Roche Molecular Systems, Inc. is one of the broader-portfolio assignees in the PatentsView dataset. By volume, Roche sits between Mstar Semiconductor, Inc. (399 patents, rank #1,079) and Stats Chippac Pte. Ltd. (392 patents, rank #1,087) - the closest US assignees by grant volume. The composite Innovation Score of 57.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 185 grants, compared with 210 in the 2015–2019 window, a -12% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Roche Molecular Systems, Inc.'s 11.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while a multi-domain presence across 67 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Molecular Systems, Inc. against peers pursuing similar technology classes.

Who files at Roche's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Roche holds 395 patents at rank #1,083, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Roche

By rank, the assignees closest to #1,083 in granted patent volume.

Leaders in C12Q (Measuring OR Testing Processes Involving Enzymes)

Other assignees with the most granted patents in Roche's primary technology class.

Roche's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). This entry sits in this band. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

102030405060 20152016201720182019202020212022202320242025 14
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Roche Molecular Systems, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 32 8.1%
2016 54 13.7%
2017 34 8.6%
2018 55 13.9%
2019 35 8.9%
2020 50 12.7%
2021 32 8.1%
2022 26 6.6%
2023 30 7.6%
2024 33 8.4%
2025 14 3.5%

Which technologies does Roche Molecular Systems, Inc. patent most?

Top 15 of 67 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Simple
Velocity Declining

Where it ranks

Overall rank by patents

#1,083

Across all tracked assignees

Innovation Score

57.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Roche Molecular Systems, Inc. hold?
Roche Molecular Systems, Inc. holds 395 US granted patents filed between 2015 and 2025, spanning 67 technology areas.
What is Roche Molecular Systems, Inc.'s Innovation Score?
Roche Molecular Systems, Inc. has an Innovation Score of 57.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Roche Molecular Systems, Inc. focus on?
Roche Molecular Systems, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 220 patents. The company has filed patents in 67 CPC subclasses total.
Is Roche Molecular Systems, Inc.'s patent filing rate increasing or decreasing?
Roche Molecular Systems, Inc.'s recent filing velocity is -12% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Roche Molecular Systems, Inc.'s patents?
Roche Molecular Systems, Inc.'s patents average 11.7 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the Roche Molecular Systems, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Roche's 395 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Roche ranks #1,083 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q - see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.